On January 7th 2013, Sequenom (NASDAQ:SQNM) was torpedoed when Illumina (NASDAQ:ILMN) announced their acquisition of Verinata and their prenatal diagnostic screen, Verifi. This decision was widely considered a head scratcher. Verifi at the time had around 7% US market share, yet Illumina paid $350 million plus an opportunity to earn another $100 million based upon certain deliverables. What made this announcement so curious was that Illumina already appeared to be in the driver's seat as the best derivative investment for this nascent market. Everyone else was fighting tooth and nail to survive. Patent survivability was being attacked in the courts and there was a constant fight for reimbursements. Illumina on the other hand, sold the sequencing...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|